Taking BioPharma’s Financial Pulse: What Do Investors Want?

The COVID-19 pandemic sent out an SOS for effective diagnostics and treatments, spurring a spike in biopharmaceutical research and funding. While funding contracted after peaking in 2021, the outlook for investments in support of biopharmaceutical innovation is brighter than it has been at any time since the start of the pandemic.

Nearly five years later, today’s investors have different interests and less risk tolerance. This industry outlook report digs into three trends in research and funding—and what they mean for drug developers and investors:

• Drug development and biomarker detection are expected to advance dramatically with AI and machine learning applications—but it won’t be overnight. 
• Therapeutics are getting to clinical trials—and on the market—faster than ever before with high-throughput experimentation.
• Promising gene therapies are winning FDA approval, a groundbreaking step in the treatment of debilitating diseases.

​